This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.
Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the
Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a
s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.
After a long haul, Merck &Co's Zontivity has become the first drug in the new protease-activated receptor-1 (PAR-1) antagonist class to be approved for marketing in the ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1
Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....